Torrent Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Samir Mehta

Chief Executive Officer (CEO)

₹260.0m

Compensación total

Porcentaje del salario del CEO	0.02%
Permanencia del CEO	35.8yrs
Participación del CEO	0.0002%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	2.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Samir Mehta en comparación con los beneficios de Torrent Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	₹18b
Jun 30 2024	n/a	n/a	₹17b
Mar 31 2024	₹260m	₹40k	₹17b
Dec 31 2023	n/a	n/a	₹15b
Sep 30 2023	n/a	n/a	₹13b
Jun 30 2023	n/a	n/a	₹13b
Mar 31 2023	₹230m	₹40k	₹12b
Dec 31 2022	n/a	n/a	₹8b
Sep 30 2022	n/a	n/a	₹8b
Jun 30 2022	n/a	n/a	₹8b
Mar 31 2022	₹200m	₹40k	₹8b
Dec 31 2021	n/a	n/a	₹12b
Sep 30 2021	n/a	n/a	₹13b
Jun 30 2021	n/a	n/a	₹13b
Mar 31 2021	₹200m	₹40k	₹13b
Dec 31 2020	n/a	n/a	₹12b
Sep 30 2020	n/a	n/a	₹12b
Jun 30 2020	n/a	n/a	₹11b
Mar 31 2020	₹200m	₹40k	₹10b
Dec 31 2019	n/a	n/a	₹6b
Sep 30 2019	n/a	n/a	₹6b
Jun 30 2019	n/a	n/a	₹5b
Mar 31 2019	₹150m	₹40k	₹4b
Dec 31 2018	n/a	n/a	₹8b
Sep 30 2018	n/a	n/a	₹6b
Jun 30 2018	n/a	n/a	₹7b
Mar 31 2018	₹150m	₹40k	₹7b

Compensación vs. Mercado: La compensación total de Samir($USD3.08M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD1.10M).

Compensación vs. Ingresos: La compensación de Samir ha sido consistente con los resultados de la empresa en el último año.

CEO

Samir Mehta (60 yo)

35.8yrs

Permanencia

₹260,040,000

Compensación

Mr. Samir Uttamlal Mehta, B.Com., MBA serves as a Managing Director of Torrent Pharmaceuticals Limited since 1989. Mr. Mehta served as Managing Director of Torrent Power Limited. Mr. Mehta has been associa...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Samir Mehta	Executive Chairman & MD	no data	₹260.04m	0.00024% ₹ 2.5m
Aman Mehta	Whole-Time Director	2.3yrs	₹65.88m	0.000060% ₹ 630.7k
Sudhir Menon	Chief Financial Officer	6.2yrs	₹16.30m	sin datos
Chintan Trivedi	Company Secretary & Compliance Officer	2.3yrs	sin datos	sin datos
Jaydip Bhatt	Vice President of Human Resource	no data	₹6.56m	sin datos
Ashish Hajarnish	Executive Director	less than a year	₹8.25m	sin datos
Abdullah Said Al Abri	Chief Customer Service Officer	3.4yrs	sin datos	sin datos
Sanjay Gupta	President and CEO of Torrent Pharma USA	no data	sin datos	sin datos

2.3yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 500420 se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Samir Mehta	Executive Chairman & MD	35.8yrs	₹260.04m	0.00024% ₹ 2.5m
Aman Mehta	Whole-Time Director	2.3yrs	₹65.88m	0.000060% ₹ 630.7k
Ashish Hajarnish	Executive Director	less than a year	₹8.25m	sin datos
Sudhir Mehta	Chairman Emeritus	10.3yrs	sin datos	0.00030% ₹ 3.2m
Nikhil Khattau	Independent Director	1.1yrs	₹2.60m	sin datos
Manish Choksi	Independent Director	2.3yrs	₹4.30m	sin datos
Ameera Shah	Independent Director	6.3yrs	₹4.90m	0.00050% ₹ 5.3m
Nayantara Bali	Independent Director	5.7yrs	₹6.70m	sin datos
Jinal Mehta	Non-Executive Director	less than a year	sin datos	sin datos
Maurice Chagnaud	Independent Director	2.5yrs	₹6.30m	sin datos

2.4yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de 500420 no se considera experimentada (2.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Torrent Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Torrent Pharmaceuticals Limited Announces Promotion of Ashish Hajarnis as Executive Director from Vice President

High number of new directors

Torrent Pharmaceuticals Limited, Annual General Meeting, Jul 23, 2024

Torrent Pharmaceuticals Limited Announces Stepping Down of Jinesh Shah as the Director, Effective from 23 July 2024

Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024

Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director

Recent updates

Torrent Pharma Promoter Reportedly to Sell Up to 2.9% Stake Via Block Deal on October 30

Price target increased by 7.4% to ₹3,587

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Alkem Reportedly Joins $3 Billion Race for JB Chem as Torrent Pauses Talks

Torrent Pharma Reportedly is Said to Seek Raising $3 Billion for KKR's Stake in JB Chemicals

Torrent Pharmaceuticals Reportedly in Talks to Acquire KKR’s Stake in JB Chemicals

Price target increased by 8.1% to ₹3,133

Torrent Pharmaceuticals Limited Announces Promotion of Ashish Hajarnis as Executive Director from Vice President

Torrent Pharmaceuticals Limited to Report Q1, 2025 Results on Jul 23, 2024

High number of new directors

Torrent Pharmaceuticals Limited, Annual General Meeting, Jul 23, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Torrent Pharmaceuticals Limited Announces Stepping Down of Jinesh Shah as the Director, Effective from 23 July 2024

Torrent Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 24, 2024

Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024

Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director

Upcoming dividend of ₹22.00 per share at 0.8% yield

Price target increased by 7.1% to ₹2,427

Dividend increased to ₹22.00

Third quarter 2024 earnings: EPS exceeds analyst expectations

Torrent Pharmaceuticals Limited Announces Interim Dividend, Payable on or around 23 February, 2024

Torrent Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 02, 2024

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Torrent Pharmaceuticals Limited to Report Q2, 2024 Results on Oct 23, 2023

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Food and Drug Administration Issues an Establishment Inspection Report for the Torrent Pharmaceuticals Limited's Manufacturing Facility At Dahej, Gujarat

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Price target increased by 8.1% to ₹2,037

Torrent Pharmaceuticals Limited Declares Final Dividend for the Financial Year Ended 31 March, 2023

Full year 2023 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 07, 2023

Torrent Pharmaceuticals Limited, Annual General Meeting, Aug 07, 2023

Torrent Pharmaceuticals Limited Recommends Final Dividend, Payable on or Around 14 August, 2023

Full year 2023 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Torrent Pharmaceuticals Limited Approves an Interim Dividend, Payable on or Around 14 February 2023

Torrent Pharmaceuticals Limited to Report Q3, 2023 Results on Jan 25, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Torrent Pharmaceuticals Limited (BSE:500420) completed the acquisition of Curatio Healthcare (I) Pvt Ltd.

Torrent Pharmaceuticals Limited to Report Q2, 2023 Results on Oct 21, 2022

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Curatio Healthcare (I) Pvt Ltd for INR 20 billion.

Torrent Pharma Reportedly Set to Acquire Curatio

Less than half of directors are independent

Torrent Pharmaceuticals Announces Appointment of Aman Mehta as Director on the Board of Torrent Pharma from 1st August, 2022

Price target increased to ₹1,719

Torrent Pharmaceuticals Limited to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited, Annual General Meeting, Jul 29, 2022

Full year 2022 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Torrent Pharmaceuticals Limited Recommends Special Dividend, Payable on or Around 4 August, 2022

Insufficient new directors

Torrent, JB Chemicals Reportedly in Final Race to Acquire Curatio Healthcare

Insufficient new directors

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings released: EPS ₹18.63 (vs ₹18.32 in 2Q 2021)

Full year 2021 earnings released: EPS ₹73.98 (vs ₹60.56 in FY 2020)

Independent Non Executive Director recently bought ₹20m worth of stock

Upcoming dividend of ₹15.00 per share

Independent Non Executive Director recently bought ₹5.0m worth of stock

Torrent Pharmaceuticals Limited Recommends Final Dividend, Payable on or Around July 30, 2021